{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:23:58Z","timestamp":1783596238217,"version":"3.55.0"},"reference-count":20,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Dry Eye Disease (DED) is a multifactorial condition with an impact on quality of life and an often suboptimal response to conventional lubricants. This study aimed at evaluating the real-world efficacy, tolerability, and patient adherence of a therapy with a novel ophthalmic solution containing Ribohyal, a riboflavin\u2013hyaluronic acid complex, used in patients with DED. Methods: This national survey included data from adult patients with clinically diagnosed DED treated with Lacrinova eye drops (4 times\/day for 3 months) whose data were collected from 82 Italian ophthalmologists. Patients were assessed before (T0) and after treatment (T1). Outcomes included patient-reported symptoms for 9 domains (0\u201310 numerical rating scale), objective clinical parameters (best-corrected visual acuity [BCVA], break-up time [BUT], and corneal fluorescein staining [CFS]), and treatment acceptability. Results: Data from 2993 patients (5986 eyes) were analyzed. Improvements were observed across all 9 symptom domains, with reductions ranging from 53% to 60% (all p &lt; 0.001). BCVA and BUT significantly improved (from 0.08 \u00b1 0.22 at T0 to 0.06 \u00b1 0.19 logMAR at T1 and from 9.20 \u00b1 4.49 to 11.85 \u00b1 4.66 s at T1, respectively, both p &lt; 0.001). The prevalence of CFS decreased from 42.0% to 23.4% (p &lt; 0.001). Treatment acceptability was high, with mean scores of 8.88\u00b1 1.49 for tolerability, 8.55 \u00b1 1.63 for adherence, and 8.62 \u00b1 1.55 for perceived efficacy. No relevant adverse events were reported. Conclusions: Lacrinova eye drops demonstrated significant improvements in both symptoms and clinical signs of DED, with excellent tolerability and adherence. These findings support its use as an effective therapeutic option in routine clinical practice, although controlled studies are warranted to confirm the efficacy.<\/jats:p>","DOI":"10.3390\/jcm15145367","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:16:22Z","timestamp":1783592182000},"page":"5367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0956-4925","authenticated-orcid":false,"given":"Filippo","family":"Lixi","sequence":"first","affiliation":[{"name":"Eye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Madalina","family":"Timofte-Zorila","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara-Ioana","family":"Tomi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rapisarda","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Enna \u201cKore\u201d, Piazza dell\u2019Universit\u00e0, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-7322","authenticated-orcid":false,"given":"Marco","family":"Messina","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Surgical Sciences, Section of Ophthalmology, University of Perugia, S. Maria della Misericordia Hospital, 61029 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Lacrinova Experience Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III Diagnostic Methodology","volume":"279","author":"Wolffsohn","year":"2025","journal-title":"Am. J. Phthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29213","DOI":"10.1038\/s41598-025-15633-1","article-title":"Light discomfort thresholds under different lighting conditions in healthy subjects and dry eye patients","volume":"15","author":"Lixi","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/NHH.0000000000000652","article-title":"Dry Eye Disease: Prevalence, Assessment, and Management","volume":"36","author":"Rouen","year":"2018","journal-title":"Home Healthc. Now"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS DEWS III Management and Therapy Report","volume":"279","author":"Jones","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/17512433.2025.2543380","article-title":"Current and emerging pharmacological treatment options for patients with dry eye disease","volume":"18","author":"Cukurova","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e35527","DOI":"10.1016\/j.heliyon.2024.e35527","article-title":"Modified Sodium hyaluronate conjugated to riboflavin (Har\u00ae 0.1%) as lubricant eyedrops in the treatment of dry eye: A prospective randomised study","volume":"10","author":"Caruso","year":"2024","journal-title":"Heliyon"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.8.6.2","article-title":"Physicochemical Properties of Hyaluronic Acid-Based Lubricant Eye Drops","volume":"8","author":"Aragona","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OPTO.S350185","article-title":"Artificial Tears: A Systematic Review","volume":"15","author":"Semp","year":"2023","journal-title":"Clin. Optom."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/aos.15159","article-title":"Hyaluronic acid in the treatment of dry eye disease","volume":"100","author":"Hynnekleiv","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"Rebamipide Ophthalmic Suspension Phase 3 Study Group. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/cxo.13111","article-title":"Optical quality in patients with dry eye before and after treatment","volume":"104","author":"Gao","year":"2021","journal-title":"Clin. Exp. Optom."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/bjophthalmol-2018-312333","article-title":"Effects of tear film dynamics on quality of vision","volume":"102","author":"Koh","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14965","DOI":"10.1039\/D0RA00417K","article-title":"Reaction-diffusion model as framework for understanding the role of riboflavin in \u201ceye defence\u201d formulations","volume":"10","author":"Caruso","year":"2020","journal-title":"RSC Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.33549\/physiolres.933759","article-title":"Effects of an antioxidant protective topical formulation on eye exposed to ultraviolet-irradiation: A study in rabbit animal model","volume":"67","author":"Vizzarri","year":"2018","journal-title":"Physiol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Uchino, M., Yokoi, N., Shimazaki, J., Hori, Y., Tsubota, K., and on behalf of the Japan Dry Eye Society (2022). Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J. Clin. Med., 11.","DOI":"10.3390\/jcm11020367"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Labetoulle, M., Benitez-Del-Castillo, J.M., Barabino, S., Herrero Vanrell, R., Daull, P., Garrigue, J.S., and Rolando, M. (2022). Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052434"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DDDT.S207743","article-title":"An Updated Systematic Review with Meta-Analysis of Randomized Trials on Topical Cyclosporin a for Dry-Eye Disease","volume":"14","author":"Tuan","year":"2020","journal-title":"Drug Des. Devel Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:37:14Z","timestamp":1783593434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":20,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145367"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145367","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}